Xpovio’s Solid Tumor Debut Faces Likely Three-Year Delay

 
• By Alaric DeArment
  
Cancer
Karyopharm said the FDA told it during a meeting that topline trial results would not likely be sufficient for Xpovio's approval in endometrial cancer • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category